Personalized cancer vaccine may enhance checkpoint inhibitor activityJune 25, 2020ImmunotherapyBreast CancerGastroenterologyGenitourinary CancerGynecologic CancerHead & Neck/Thyroid CancersMelanoma
More than 10,000 excess cancer deaths because of COVID-19 delaysJune 25, 2020Preventive CareCOVID-19 UpdatesBreast CancerGastroenterologyPatient & Survivor CareGastrointestinal Cancer
Cardiology care ups CV monitoring, BP control in HER2+ breast cancerJune 19, 2020Breast CancerPreventive Care
American Cancer Society update: ‘It is best not to drink alcohol’June 9, 2020Preventive CareBreast CancerGastroenterologyGenitourinary CancerGynecologic CancerHead & Neck/Thyroid CancersLung Cancer
Can an app guide cancer treatment decisions during the pandemic?June 9, 2020Patient & Survivor CareBreast CancerCNS/Brain CancerCOVID-19 UpdatesGastroenterologyGenitourinary CancerGynecologic Cancer
‘A good and peaceful death’: Cancer hospice during the pandemicJune 5, 2020Patient & Survivor CareBreast CancerCNS/Brain CancerGastroenterologyGenitourinary CancerGynecologic CancerHead & Neck/Thyroid Cancers
Germline testing in advanced cancer can lead to targeted treatmentJune 3, 2020Mixed TopicsBreast CancerCNS/Brain CancerGastroenterologyGenitourinary CancerGynecologic CancerHead & Neck/Thyroid Cancers
TILs and PET-CT can predict pCR in HER2-positive metastatic breast cancerJune 2, 2020Breast CancerMetastatic Breast Cancer
Treating primary tumor doesn’t improve OS in stage IV breast cancerJune 1, 2020Breast CancerASCO Breast CancerMetastatic Breast Cancer
Pyrotinib bests lapatinib in HER2+ metastatic breast cancerMay 31, 2020Breast CancerMetastatic Breast CancerASCO Breast Cancer
Expanding the role of PARP inhibitors in breast cancerMay 31, 2020Breast CancerASCO Breast CancerMetastatic Breast Cancer
ALTERNATE trial: No fulvestrant benefit in locally advanced ER+ HER2– breast cancerMay 31, 2020Breast CancerASCO Breast Cancer
Tucatinib improves PFS, OS in HER2+ breast cancer with brain metastasesMay 30, 2020Breast CancerASCO Breast CancerMetastatic Breast Cancer
TRAIN-2: Anthracyclines added toxicity, with no increased efficacy, in HER2+ breast cancerMay 30, 2020Breast CancerASCO Breast Cancer
Capecitabine maintenance improved DFS, not OS, in TNBC patientsMay 30, 2020Breast CancerASCO Breast Cancer
